MarketPulse

hematologic malignancies

2 articles
The Motley FoolThe Motley Fool··Motley Fool Transcribing

Curis Posts Surprise Profit on Erivedge Sale, Pivots to Lymphoma Pipeline

$CRIS reports $19.4M Q4 earnings from one-time Erivedge sale; refocuses on PCNSL and CLL studies with $20.2M PIPE funding.
CRISearningsclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

TScan Advances Allogeneic Cell Therapy Pipeline With FDA IND Clearances and Trial Enrollment Milestones

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.
TCRXclinical trialTCR-T therapy